{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:09:18Z","timestamp":1761948558853,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Institut de Recherche Pierre Fabre","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00213-019-05387-w","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T06:02:52Z","timestamp":1574748172000},"page":"519-527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [11C]-(+)-PHNO"],"prefix":"10.1007","volume":"237","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2142-6353","authenticated-orcid":false,"given":"Mark","family":"Slifstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anissa","family":"Abi-Dargham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ragy R","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond F","family":"Suckow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas B","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaitanya R","family":"Divgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Sokoloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovic","family":"Leriche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Carberry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichi","family":"Oya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon K","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marl\u00e8ne","family":"Guiraud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Montagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Gaudoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Tonner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"issue":"11","key":"5387_CR1","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1038\/s41386-019-0355-2","volume":"44","author":"I Bitter","year":"2019","unstructured":"Bitter I, Lieberman JA, Gaudoux F, Sokoloff P, Groc M, Chavda R et al (2019) Randomized, double-blind, placebo-controlled study of F17464, a preferential D3-antagonist, in the treatment of acute exacerbation of schizophrenia. Neuropsychopharmacology 44(11):1917\u20131924","journal-title":"Neuropsychopharmacology"},{"key":"5387_CR2","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0897190008330200","volume":"22","author":"EL Breden","year":"2009","unstructured":"Breden EL, Liu MT, Dean SR (2009) Metabolic and cardiacs side effects of second-generation antipsychotics: What every clinician should know. J Pharm Pract 22:478\u2013488","journal-title":"J Pharm Pract"},{"key":"5387_CR3","first-page":"51","volume":"42","author":"RR Conley","year":"2005","unstructured":"Conley RR, Kelly DL (2005) Second generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. J Psychiatr Relat Sci 42:51\u201360","journal-title":"J Psychiatr Relat Sci"},{"issue":"4","key":"5387_CR4","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/schbul\/sbu170","volume":"41","author":"PF Fusar-Poli","year":"2015","unstructured":"Fusar-Poli PF, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, McGuire P (2015) Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull 41(4):892\u2013899","journal-title":"Schizophr Bull"},{"issue":"6","key":"5387_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/syn.21535","volume":"66","author":"JD Gallezot","year":"2012","unstructured":"Gallezot JD, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D, Singhal T, Slifstein M, Fowles K, Ding YS, Huang Y, Laruelle M, Carson RE, Rabiner EA (2012) Affinity and selectivity of [(1)(1)C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 66(6):489\u2013500","journal-title":"Synapse"},{"issue":"6","key":"5387_CR6","doi-asserted-by":"publisher","first-page":"960","DOI":"10.2967\/jnumed.113.132928","volume":"55","author":"JD Gallezot","year":"2014","unstructured":"Gallezot JD, Zheng MQ, Lim K, Lin SF, Labaree D, Matuskey D, Huang Y, Ding YS, Carson RE, Malison RT (2014) Parametric imaging and test-retest variability of 11C-(+)-PHNO binding to D2\/D3 dopamine receptors in humans on the high-resolution research tomograph PET scanner. J Nucl Med 55(6):960\u2013966","journal-title":"J Nucl Med"},{"issue":"19-20","key":"5387_CR7","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","volume":"233","author":"RR Girgis","year":"2016","unstructured":"Girgis RR, Slifstein M, D'Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kap\u00e1s M, Abi-Dargham A, Rakhit A (2016) Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3\/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacol 233(19-20):3503\u20133512","journal-title":"Psychopharmacol"},{"issue":"6","key":"5387_CR8","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/archgenpsychiatry.2009.43","volume":"66","author":"A Graff-Guerrero","year":"2009","unstructured":"Graff-Guerrero A, Mamo D, Shammi CM, Mizrahi R, Marcon H, Barsoum P, Rusjan P, Houle S, Wilson AA, Kapur S (2009) The effect of antipsychotics on the high-affinity state of D-2 and D-3 receptors A positron emission tomography study with [C-11]-(+)-PHNO. Arch Gen Psychiatry 66(6):606\u2013615","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"5387_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0163-7258(82)90051-1","volume":"16","author":"NH Holford","year":"1982","unstructured":"Holford NH, Sheiner LB (1982) Kinetics of pharmacologic response. Pharmacol Ther 16(2):143\u2013166","journal-title":"Pharmacol Ther"},{"issue":"9","key":"5387_CR10","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","volume":"27","author":"RB Innis","year":"2007","unstructured":"Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27(9):1533\u20131539","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3 Pt 1","key":"5387_CR11","first-page":"153","volume":"4","author":"AA Lammertsma","year":"1996","unstructured":"Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuro Image 4(3 Pt 1):153\u2013158","journal-title":"Neuro Image"},{"issue":"Suppl. 4","key":"5387_CR12","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.1016\/S0924-977X(03)91703-2","volume":"13","author":"Y Lecrubier","year":"2003","unstructured":"Lecrubier Y (2003) A partial D3 receptor agonist in schizophrenia. Eur Neuropsychopharmacol 13(Suppl. 4):S167\u2013S168","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"5387_CR13","first-page":"231","volume":"49","author":"B Levant","year":"1997","unstructured":"Levant B (1997) The D-3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 49(3):231\u2013252","journal-title":"Pharmacol Rev"},{"key":"5387_CR14","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209\u20131223","journal-title":"N Engl J Med"},{"issue":"3","key":"5387_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/01.WCB.0000048520.34839.1A","volume":"23","author":"D Martinez","year":"2003","unstructured":"Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y, Cooper T, Kegeles L, Zarahn E, Abi-Dargham A, Haber SN, Laruelle M (2003) Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23(3):285\u2013300","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1-3","key":"5387_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.schres.2011.05.005","volume":"131","author":"R Mizrahi","year":"2011","unstructured":"Mizrahi R, Agid O, Borlido C, Suridjan I, Rusjan P, Houle S, Remington G, Wilson AA, Kapur S (2011) Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophr Res 131(1-3):63\u201368","journal-title":"Schizophr Res"},{"key":"5387_CR17","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/syn.20658","volume":"63","author":"E Rabiner","year":"2009","unstructured":"Rabiner E, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R, Diwan M, Wilson AA, McCormick P, Gentile G, Gunn RN, Laruelle MA (2009) In vivo quantification of regional dopamine-D3 receptor binding potential of (+)PHNO: studies in non-hman primates and transgenic mice. Synapse 63:782\u2013793","journal-title":"Synapse"},{"key":"5387_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/JCP.0b013e31820e4818","volume":"31","author":"L Redden","year":"2011","unstructured":"Redden L, Rendenbach-Mueller B, Abi-Saab WM, Katz DA, Goenjian A, Robieson WZ, Wang Y, Goss SL, Greco N, Saltarelli MD (2011) A double-blind, randomized, placebo-controlled study of the dopamine D(3) receptor antagonist ABT-925 in patients with acute schizophrenia. J Clin Psychopharmacol 31:221\u2013225","journal-title":"J Clin Psychopharmacol"},{"key":"5387_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.phrs.2015.07.022","volume":"101","author":"LE Rojo","year":"2015","unstructured":"Rojo LE, Gaspar PA, Silvia H et al (2015) Metabolic syndrome and obesity among users of second-generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res 101:74\u201385","journal-title":"Pharmacol Res"},{"issue":"5","key":"5387_CR20","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/jcbfm.2012.208","volume":"33","author":"C Salinas","year":"2013","unstructured":"Salinas C, Weinzimmer D, Searle G, Labaree D, Ropchan J, Huang Y, Rabiner EA, Carson RE, Gunn RN (2013) Kinetic analysis of drug-target interactions with PET for characterization of pharmacological hysteresis. J Cereb Blood Flow Metab 33(5):700\u2013707","journal-title":"J Cereb Blood Flow Metab"},{"key":"5387_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1176\/appi.ajp.159.4.561","volume":"159","author":"MJ Sernyak","year":"2002","unstructured":"Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R (2002) Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Clin Psychiatry 159:561\u2013566","journal-title":"Am J Clin Psychiatry"},{"key":"5387_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/187152706784111551","volume":"5","author":"P Sokoloff","year":"2006","unstructured":"Sokoloff P, Diaz J, LeFoll B, Guillin O, Leriche L, Bezard E, Gross C (2006) The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5:25\u201343","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"2","key":"5387_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00210-012-0797-0","volume":"386","author":"P Sokoloff","year":"2013","unstructured":"Sokoloff P, Leriche L, Diaz J, Louvel J, Pumain R (2013) Direct and indirect interactions of the dopamine D3 receptor with glutamate pathways: implications for the treatment of schizophrenia. Naunyn Schmiedeberg's Arch Pharmacol 386(2):107\u2013124","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"unstructured":"Sokoloff P, Brunner V, Tonner F, Gaudoux F, Girgis R, Slifstein M, Abi-Dargham A, Leriche L (2014). F17464, a selective dopamine D3 antagonist\/serotonin 5-HT1A partial agonist, as a clinical candidate with wide ranging antipsychotic-like activity in models of dopamine and glutamate dysfunctions. Neuropsychopharmacology 39 S571 ACNP 53rd Annual Meeting W153:S571","key":"5387_CR24"},{"issue":"1","key":"5387_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.neuroimage.2010.06.044","volume":"54","author":"AC Tziortzi","year":"2011","unstructured":"Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M, Laruelle M, Rabiner EA, Gunn RN (2011) Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. NeuroImage 54(1):264\u2013277","journal-title":"NeuroImage"},{"issue":"12","key":"5387_CR26","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1021\/jm050155n","volume":"48","author":"AA Wilson","year":"2005","unstructured":"Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D, Houle S, Seeman P, Ginovart N (2005) Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin -9-ol as a potential radiotracer for in vivo Imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48(12):4153\u20134160","journal-title":"J Med Chem"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-019-05387-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-019-05387-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-019-05387-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:26:37Z","timestamp":1606263997000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-019-05387-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["5387"],"URL":"https:\/\/doi.org\/10.1007\/s00213-019-05387-w","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"type":"print","value":"0033-3158"},{"type":"electronic","value":"1432-2072"}],"subject":[],"published":{"date-parts":[[2019,11,26]]},"assertion":[{"value":"1 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The employers of AA-D, MS, RRG, RFS, and TBC received payment from Pierre Fabre for research support\/services. AM and MG are employees of Institut de Recherche Pierre Fabre. VB, LL, FT, and PS were employees at the time of their involvement in the study. CD, PC, SJ, and SO declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}